Back to top
more

MEI Pharma (MEIP)

(Delayed Data from NSDQ)

$3.04 USD

3.04
63,083

0.00 (0.00%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $3.09 +0.05 (1.64%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer

by Zacks Equity Research

Bristol-Myers Squibb Company (BMY) announced that the FDA has accepted and granted a priority review designation to the supplemental Biologics License Application for the label expansion of Opdivo to patients with hepatocellular carcinoma (HCC).

    Achaogen's Plazomicin Gets Breakthrough Therapy Designation

    by Zacks Equity Research

    Achaogen, Inc. (AKAO) announced that the FDA granted Breakthrough Therapy designation for plazomicin, for the treatment of serious bacterial infections due to MDR enterobacteriaceae, including carbapenem-resistant enterobacteriaceae.

      Catalyst Pharmaceuticals Focuses on Development of Firdapse

      by Zacks Equity Research

      We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX) on May 22.

        Calithera Biosciences (CALA) Jumps: Stock Moves 17% Higher

        by Zacks Equity Research

        Calithera Biosciences, Inc. (CALA) shares rise over 17% in the last trading session.

          Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion

          by Zacks Equity Research

          Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.

            Alexion's (ALXN) Strensiq Results Positive in Long-Term Study

            by Zacks Equity Research

            Alexion Pharmaceuticals, Inc. (ALXN) announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society (ECTS) Congress in Austria.

              Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss

              by Zacks Equity Research

              Kamada Ltd. (KMDA) reported adjusted loss of 11 cents in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 3 cents.

                Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now

                by Zacks Equity Research

                On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI).

                  Minerva (NERV) Provides Phase III Development Strategy for MIN-101

                  by Zacks Equity Research

                  Minerva Neurosciences, Inc. (NERV) announced plans for its phase III and phase IV clinical development of pipeline candidate MIN-101.

                    Ionis (IONS) Stock Falls Despite Positive Inotersen Data

                    by Zacks Equity Research

                    Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.